Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,043.34 +6.19 (+0.60%)

Streaming Delayed Price Updated: 3:11 PM EST, Feb 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Krispy Kreme Jumps After Hours Following Kash Patel's Stake Reveal ↗

September 18, 2025

Krispy Kreme's stock rose 3.81% after hours on Wednesday, following FBI Director Kash Patel's testimony about his stock purchase, despite a 68.28% drop in 2025.

Via Benzinga

1 Mega-Cap Stock with Impressive Fundamentals and 2 We Question

September 18, 2025

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their...

Via StockStory

Topics Artificial Intelligence

Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up ↗

September 17, 2025

The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity.

Via Stocktwits

FBI Director Kash Patel Bought 2 Stocks In 2025 — One's Already A Meme Favorite ↗

September 17, 2025

FBI Director Kash Patel was asked about two stocks he bought earlier this year by a member of Congress on Wednesday and gave a surprising answer. The transactions come as members of Congress are...

Via Benzinga

Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial ↗

September 17, 2025

Via Stocktwits

Why Is Eli Lilly’s Stock Slipping Premarket? ↗

September 17, 2025

Via Stocktwits

Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside ↗

September 16, 2025

Via Stocktwits

Why Novo Nordisk Stock Popped Today ↗

September 17, 2025

Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now?

Via The Motley Fool

Congressional Trading Report: Rep. David Taylor Sold Over $2K In Alphabet Stock ↗

September 17, 2025

Via Benzinga

GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years ↗

September 17, 2025

GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug and device capabilities.

Via Benzinga

Topics Artificial Intelligence

Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss? ↗

September 17, 2025

Eli Lilly's orforglipron showed significant weight loss, improved blood sugar, and reduced inflammation in adults with obesity or overweight in a Phase 3 trial.

Via Benzinga

Apple To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

September 17, 2025

Via Benzinga

This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

September 17, 2025

Via Benzinga

Dow Futures Stall Ahead Of Fed’s Interest Rate Decision Today: WDAY, MSFT, GOOGL, NVDA Among Stocks To Watch ↗

September 17, 2025

While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures fell 0.07%.

Via Stocktwits

Topics ETFs Economy Government

GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America ↗

September 16, 2025

The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.

Via Stocktwits

Topics Artificial Intelligence Government World Trade

Why Eli Lilly Stock Was a Winner Today ↗

September 16, 2025

A news article implied that the company might have an advantage in the weight loss drug race.

Via The Motley Fool

Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition

September 16, 2025

Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable...

Via MarketMinute

Topics Earnings Economy Intellectual Property

FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims ↗

September 16, 2025

The FDA finds Eli Lilly's video on Zepbound and Mounjaro misleading, citing omissions of serious risks.

Via Benzinga

Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing ↗

September 16, 2025

Eli Lilly plans a $5 billion Virginia facility to expand drug production, create 650 jobs, and use advanced tech for cancer and autoimmune treatments.

Via Benzinga

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment ↗

September 16, 2025

Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients.

Via Benzinga

3 Undervalued Healthcare Stocks to Buy Now While They're Cheap ↗

September 16, 2025

In an otherwise hot stock market, healthcare stocks are underperforming.

Via The Motley Fool

Forecasting The Future: 10 Analyst Projections For Eli Lilly ↗

September 16, 2025

Via Benzinga

3 Great High-Yield Dividend Stocks to Buy in September ↗

September 16, 2025

Quality yields above 6% from three very different market sectors.

Via The Motley Fool

Here Is My Top Stock Pick Among the Weight Loss Industry Leaders ↗

September 16, 2025

The weight loss drug market may reach $95 billion within five years.

Via The Motley Fool

Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition

September 15, 2025

Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance....

Via MarketMinute

Topics Economy Intellectual Property

AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit ↗

September 15, 2025

AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows.

Via Benzinga

Topics Government

Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook

September 15, 2025

Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health

September 15, 2025

The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor...

Via MarketMinute

Why Novo Nordisk Stock Popped Today ↗

September 15, 2025

A price cut could help get Novo Nordisk stock back in the race against Eli Lilly.

Via The Motley Fool

1 Stock That Should Be in Every Investor's Portfolio ↗

September 15, 2025

Eli Lilly has seen weakness in its stock price year to date. I think it's a short-term problem.

Via The Motley Fool

< Previous 1 2

...

29 30 31 32 33 34 35 36 37

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.